Phase ii clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancerJACKMAN, David M; YEAP, Beow Y; FREIDLIN, Boris et al.Journal of clinical oncology. 2007, Vol 25, Num 7, pp 760-766, issn 0732-183X, 7 p.Article

Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factorXIAOMIN ZHANG; AZHAR, Gohar; MISRA, Ravi P et al.American journal of physiology. Heart and circulatory physiology. 2001, Vol 49, Num 4, pp H1782-H1792, issn 0363-6135Article

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screeningJÄNNE, Pasi A; BORRAS, Ana M; DISTEL, Robert J et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 751-758, issn 1078-0432, 8 p., 1Article

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibJACKMAN, David M; HOLMES, Alison J; LINDEMAN, Neal et al.Journal of clinical oncology. 2006, Vol 24, Num 27, pp 4517-4520, issn 0732-183X, 4 p.Article